CurIOS Therapeutics is a NewCo advancing novel mRNA therapies to target virus-associated cancers. The team is comprised of physician-scientists with deep clinical, immunobiology and translational expertise. We have novel platform technologies that overcome the core challenges in the mRNA cancer therapeutic field today including: i) targeting strong, conserved tumor antigens and ii) sustaining CD8+ T cell responses. We have developed strong preclinical rationale for a vaccine candidate against Merkel cell carcinoma (MCC), a rare cancer with high unmet need that has generated significant partnering interest and developed the rationale for targeting ERVs in RCC (an indication with multibillion dollar peak annual revenue).